文献速递胸部肿瘤放疗

随机、多中心、3期研究:加速大分割放疗同步加量至大体肿瘤体积对比常规分割同步放化疗治疗不可切除III期非小细胞肺癌:韩国放射肿瘤学组09-03试验

Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-10-21

韩国放射肿瘤学组09-03三期试验比较加速大分割放疗(同步加量至大体肿瘤体积)与常规分割60 Gy放疗在不可切除III期非小细胞肺癌同步放化疗中的疗效。常规分割组124例,加速大分割组142例,两组客观缓解率、总生存、无进展生存及局部肿瘤控制率均无显著差异。该试验未证实加速2.4 Gy大分割放疗优于常规2 Gy分割。

要点

  • 加速大分割组(142例)与常规分割组(124例)的客观缓解率分别为88.1%与84.6%(P=0.612)。
  • 中位总生存加速大分割组27个月 vs 常规分割组26个月(P=0.508)。
  • ≥3级放射性肺炎和放射性食管炎的累积发生率组间无显著差异(P=0.134和P=0.539)。

核心结论

  • 该临床试验未证实加速2.4 Gy大分割放疗优于常规2 Gy分割同步放化疗用于不可切除III期非小细胞肺癌。

研究设计与样本

  • 随机、多中心、3期临床试验(韩国放射肿瘤学组09-03),不可切除III期非小细胞肺癌患者随机分为常规分割组(124例)和加速大分割组(142例)。
  • 常规分割组:计划靶区44 Gy/22次,大体肿瘤体积60 Gy/30次,6周完成,每日2 Gy。
  • 加速大分割组:计划靶区45 Gy/25次,大体肿瘤体积60 Gy/25次,5周完成,每日1.8 Gy同步加量0.6 Gy至大体肿瘤体积。
  • 所有患者接受每周紫杉醇联合顺铂同步化疗。

主要发现

  • 全部患者客观缓解率为86.5%(常规分割组84.6% vs 加速大分割组88.1%,P=0.612)。
  • 中位总生存26个月(常规分割组26个月 vs 加速大分割组27个月,P=0.508)。
  • 中位无进展生存11个月(常规分割组10个月 vs 加速大分割组13个月,P=0.295)。
  • 2年和5年局部肿瘤控制率分别为58.3%和50.7%(常规分割组62.4%和51.0% vs 加速大分割组54.0%和48.6%,P=0.615)。
  • ≥3级放射性肺炎和放射性食管炎的累积发生率组间无显著差异(P=0.134和P=0.539)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We designed the Korean Radiation Oncology Group 09-03 phase III clinical trial to compare accelerated hypofractionated radiation therapy (RT) using a concomitant boost to the gross tumor volume (GTV) with conventionally fractionated 60-Gy RT in patients with stage III unresectable non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: A conventionally fractionated RT group (arm 1; 124 patients) received a 2-Gy daily dose to a total cumulative dose of 44 Gy to the planning target volume (PTV) in 22 fractions and 60 Gy to the GTV in 30 fractions over 6 weeks. A hypofractionated RT group (arm 2; 142 patients) received a 1.8-Gy daily dose to the PTV with a synchronous boost of 0.6 Gy to the GTV, for total cumulative doses of 45 Gy to the PTV and 60 Gy to the GTV in 25 fractions over 5 weeks. All patients received concurrent weekly chemotherapy consisting of paclitaxel and cisplatin. RESULTS: The objective response rate of all patients was 86.5% (arm 1, 84.6%; arm 2, 88.1%; P = .612). The median overall survival was 26 months (arm 1, 26 months; arm 2, 27 months; P = .508). The median progression-free survival was 11 months (arm 1, 10 months; arm 2, 13 months; P = .295). The local tumor control rates at 2 and 5 years were 58.3% and 50.7%, respectively (arm 1, 62.4% and 51.0%, respectively; arm 2, 54.0% and 48.6%, respectively; P = .615). There were no significant between-group differences in the cumulative incidence of grade ≥3 radiation pneumonitis (P = .134) or radiation esophagitis (P = .539). CONCLUSIONS: This clinical trial did not confirm the superiority of accelerated 2.4-Gy hypofractionated RT compared with conventional 2-Gy fractionation in patients with unresectable stage III NSCLC undergoing concurrent chemoradiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim YH, Ahn SJ, Moon SH, et al. Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 36280151. doi:10.1016/j.ijrobp.2022.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。